Crescent Biopharma, Inc. (CBIO) |
| 11.35 -0.92 (-7.5%) 10-10 16:00 |
| Open: | 12.18 |
| High: | 12.18 |
| Low: | 11.28 |
| Volume: | 75,156 |
| Market Cap: | 158(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 13.88 |
| Resistance 1: | 12.76 |
| Pivot price: | 12.15 |
| Support 1: | 10.96 |
| Support 2: | 9.12 |
| 52w High: | 63 |
| 52w Low: | 10.83 |
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
Financials
| EPS | 0.000 |
| Book Value | 7.120 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Sat, 04 Oct 2025
Short Interest in Crescent Biopharma, Inc. (NASDAQ:CBIO) Grows By 103.8% - MarketBeat
Tue, 30 Sep 2025
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Wed, 27 Aug 2025
Stifel reiterates Buy rating on Crescent Biopharma stock at $28 target - Investing.com
Mon, 25 Aug 2025
This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Mon, 25 Aug 2025
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating - Investing.com
Mon, 18 Aug 2025
Crescent Biopharma: Chasing The Summit Hype - Seeking Alpha
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
